leisure time -WSS

leisure time

author：comprehensive 2025-09-27 22:56:55 - browse：3

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Mom launches Girl Scout troop for LGBTQ youth in Texas

leisure time

focus

WSS

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Timeline: Key moments in fight for gay rights

Biden administration plans revamp of organ transplant system

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Living organ donors deserve priority status for transplants

Cancer drug shortages should be causing more outrage

Eli Lilly’s Mounjaro succeeds in second weight

How one medical school became remarkably diverse

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

What does generative AI mean for health care? We asked experts

Living organ donors deserve priority status for transplants

focus

Patients, doctors are clashing about side effects of hormonal birth control

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Biogen nominates mother of director’s child to replace him on board

Bispecific antibodies are next new thing in cancer immunotherapy

The thinking behind the controversial eating disorder chatbot Tessa

leisure time

focus

focus

focus